Oral immunotherapy with omalizumab reverses the Th2 cell ‐like programme of regulatory T cells and restores their function

Clinical&Experimental Allergy, EarlyView.

Source: Clinical and Experimental Allergy - May 29, 2018 Category: Allergy & Immunology Authors: A. Abdel ‐Gadir , L. Schneider , A. Casini , L.‐M. Charbonnier , S. V. Little , T. Harrington , D. T. Umetsu , R. Rachid , T. A. Chatila Source Type: research